Syenex develops bioengineering technologies and tools for targeted delivery of genetic material to accelerate and advance cell and gene therapies. 

Syntax Bio is pioneering an approach to stem cell differentiation using a modified CRISPR system to regulate endogenous genes in a temporally controlled manner, mimicking human developmental processes at the epigenetic level.

Grove Biopharma is engineering synthetic biologics that can access and modulate previously “undruggable” intracellular targets, offering promising treatment avenues for neurodegenerative diseases, cancer, and beyond. 

Portal Innovations is a life sciences global venture development engine that aims to bridge the gap between scientific exploration and entrepreneurial realization. They equip early-stage life sciences companies with seed capital, wet lab space, and management expertise.